TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03750565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 - Dose A
Description: oral capsule/tablet, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 - Dose B
Description: oral capsule/tablet, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 - Dose B
Description: oral capsule/tablet, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 - Dose C
Description: oral capsule/tablet, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral capsule/tablet, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral capsule/tablet, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral capsule/tablet, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral capsule/tablet, QD
Study: NCT02300610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide orally once a day. Dose Escalation Level 1: 80 mg; Level 2: 160 mg. Dose Expansion at recommended dose level, after dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide orally once a day. Dose Escalation Level 1: 80 mg; Level 2: 160 mg. Dose Expansion at recommended dose level, after dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at 70 mg/m\^2 IV on day 1, repeated every 21 days for total of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at 70 mg/m\^2 IV on day 1, repeated every 21 days for total of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at 1000 mg/m\^2 IV on days 1, 8, repeated every 21 days for total of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at 1000 mg/m\^2 IV on days 1, 8, repeated every 21 days for total of 6 cycles.
Study: NCT02310308

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chewing gum administration
Description: Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewing gum administration
Description: Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chewing gum administration
Description: Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
Study: NCT01289522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab IV
Description: * Cetuximab 400 mg/m² over 120 minutes on day 1 of cycle 1 only.~* Cetuximab dose will be 250 mg/m² IV over 60 minutes weekly on subsequent administrations during the four cycles of chemotherapy.~* Cetuximab dose will be 500mg/m2 IV every 2 weeks during the maintenance therapy.~Drug: Cisplatin IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles~Drug: Docetaxel IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles~G-CSF support with lenograstim 150 microg./m2/day is delivered after each cycle of chemotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: No intervention, only biopsy for translational project.
Study: NCT01939912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Antiarrhythmic agent.
Study: NCT00672802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon and Placebo
Description: Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
Study: NCT02030600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Study: NCT00880217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine 80 mg/d
Description: 40-mg capsule for 3 days, followed by 80-mg capsule once daily for 39 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once daily for 42 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OROS methylphenidate HCl 54 mg/d
Description: 36-mg capsule for 3 days, followed by 54-mg capsule once daily for 39 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-31001074 3 mg/d
Description: 3-mg capsule once daily for 42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-31001074 1 mg/d
Description: 1-mg capsule once daily for 42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-31001074 10 mg/d
Description: 10-mg capsule once daily for 42 days
Study: NCT03931564

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRESERFLO Microshunt implantation
Description: The intervention consists of the microshunt implantation augmented with mitomycin C application.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: The usual care / control group will undergo a standard fornix based trabeculectomy augmented with mitomycin C application.
Study: NCT00177411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parathyroid Hormone-related Protein
Description: Parathyroid Hormone-related Protein in doses started at a 4 microgram single bolus intravenous dose. Dose will be increase to a maximum of 400 micrograms or until a dose limiting toxicity occurs at a lower dose.
Study: NCT04898881

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breast Human Milk
Description: Interventional drug is given to the neonates 2 minutes before the heel lance

Intervention type: OTHER
Group type: OTHER
Intervention: 24 % Sucrose
Description: 0.5 ml of sucrose given once 2 minutes prior to procedure
Study: NCT06195085

Intervention type: RADIATION
Intervention: CT-guided radioactive iodine-125 seed implantation
Description: The CT-guided radioactive iodine-125 seed implantation procedure mainly consisted of preoperative treatment planning, intraoperative seed implantation and postoperative dosimetric evaluation. All procedures were performed as per relevant guidelines and regulations.
Study: NCT00255177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VGX-410 (Mifepristone)
Description: VGX-410 tablets taken daily or twice daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VGX-410 (Mifepristone)
Description: VGX-410 tablets taken daily or twice daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VGX-410 (Mifepristone)
Description: VGX-410 tablets taken daily or twice daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for VGX-410 tablets taken daily or twice daily for 28 days
Study: NCT03588117

Intervention type: BEHAVIORAL
Intervention: Physician-supervised nonsurgical weight management program
Description: Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
Study: NCT01256307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training and educational program
Description: 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: educational program
Description: 8 weeks
Study: NCT01219608

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine 0.5 g/kg/day
Description: Glutamine 0.5 g/kg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine 1 g/kg/day
Description: Glutamine 1 g/kg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Enteral Nutrition
Description: Ordinary Enteral Nutrition
Study: NCT02990052

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar plating
Description: Open reduction and volar fixed-angle plate fixation of distal radius fracture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Closed reduction \& casting of distal radius fracture
Study: NCT00478959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide (Revlimid®)
Description: 25mg PO daily for 21 out of 28days per cycle
Study: NCT00407511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin will be administered orally, twice a day for 12 weeks, including 4-week dose adjustment phase followed by 8-week maintenance phase. The minimum allowable pregabalin dose during the trial will be 75 mg BID (150 mg/day) and the maximum allowable dose will be 300 mg BID (600 mg/day).
Study: NCT02094365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle
Study: NCT03786393

Intervention type: DIAGNOSTIC_TEST
Intervention: ACR 1990 fibromyalgia critters
Description: ACR 1990 fibromyalgia critters

Intervention type: DIAGNOSTIC_TEST
Intervention: ACR 1990 fibromyalgia critters
Description: ACR 1990 fibromyalgia critters
Study: NCT01541748

Intervention type: OTHER
Intervention: Axis
Description: Coloplast's Axis™ Allograft Dermis is used for anterior, posterior or combined (anterior and posterior) pelvic organ prolapse repair.
Study: NCT01675778

Intervention type: DRUG
Group type: OTHER
Intervention: Hydromorphone
Description: a fixed dose (1 mg) of hydromorphone will be given to the study subjects
Study: NCT01110941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, leucovorin, oxaliplatin
Description: S-1(20mg、25mg), capsule, 40\~60mg, Bid,p.o., day1\~7； LV (25 mg), tablet, 25mg,Bid,p.o., day1\~7； L-OHP (50 mg),injection 85mg/m2, day1. repeated at every 2 weeks cycle till disease progression.
Study: NCT01163799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept (ASP0485)
Description: Withdrawal of calcineurin inhibitor at 30 days post-transplant. Administer Alefacept 7.5 mg post-op day 0, post-op day 2 given IV; Alefacept 15 mg SQ X 12 weeks, then monthly until Month 12.
Study: NCT01980758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Gastric Plication
Description: The study will examine the effects of a type of weight loss surgery on obese adolescents age 14-19. ) The study protocol includes pre-treatment assessments followed by a 2-month education and lifestyle modification treatment program. Following surgery, comprehensive follow-up care will be provided over a 3 year period.
Study: NCT02258061

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DDD-80
Description: Basal pacing rate set to 80-bpm. Note:Patients have already pacemaker implanted before this study.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: DDD-60
Description: Basal pacing rate set to 60-bpm. Note:Patients have already pacemaker implanted before this study.
Study: NCT02619188

Intervention type: OTHER
Intervention: PUQE-form inclusion
Description: PUQE-form encompassing last 24 hours completion

Intervention type: OTHER
Intervention: PUQE-form inclusion
Description: PUQE-form encompassing last 24 hours completion

Intervention type: OTHER
Intervention: Nutritional form inclusion
Description: Food-list form encompassing last 24 hours completion

Intervention type: OTHER
Intervention: Nutritional form inclusion
Description: Food-list form encompassing last 24 hours completion

Intervention type: OTHER
Intervention: Blood sampling inclusion
Description: Measurement of biochemical nutrition marker(s); Prealbumin

Intervention type: OTHER
Intervention: Blood sampling inclusion
Description: Measurement of biochemical nutrition marker(s); Prealbumin

Intervention type: OTHER
Intervention: Intervention at discharge
Description: PUQE-form, nutritional form and Blood sampling
Study: NCT03931122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ear Size Based Method (Ambu® AuraOnce™ Laryngeal Mask Airway)
Description: The Laryngeal Mask Airway (LMA) is one of the devices used to maintain airway during general anesthesia. Its appropriate size is selected according to patients body weight as recommended by the manufacturer.~However its appropriate size can also be selected via several other methods and one of them is patients external ear size. In this study the investigators will compare external ear size based method for LMA selection with the standard weight based method for LMA size selection.~Vertical Ear length: will be measured from the most dependent portion of the lobule to the furthest portion of the auricle.~Horizontal Ear length (width): from the tragus to the furthest part of the helix horizontally.~Dimension(cm2): Vertical length (L) × Horizontal length (width-W)~LMA Size LMA Cuff Length (cm) corresponding to vertical ear length.~LMA Cuff Width (cm) corresponding to horizontal ear width.
Study: NCT03482024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC.
Study: NCT01555775

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: P-CHO supplement
Description: In the first trial, this group will drink a protein (P)-carbohydrate (CHO) supplement and in the second trial the fruit milk shake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit Milk Shake
Description: The fruit content of the milk shake will be 100 g of strawberry and the amount of banana necessary to guaranty 0.8-1.2 g CHO • kg-1 BW • h-1.
Study: NCT00204737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 20mg x 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03650647

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carious dentin removal
Description: Carious tissue removal and managing deep cavitated carious lesions in primary teeth.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carious dentin removal
Description: Carious tissue removal and managing deep cavitated carious lesions in primary teeth.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carious dentin removal
Description: Carious tissue removal and managing deep cavitated carious lesions in primary teeth.
Study: NCT05873738

Intervention type: DRUG
Intervention: Nicotine replacement
Description: Nicotine patches

Intervention type: DRUG
Intervention: Nicotine replacement
Description: Nicotine patches
Study: NCT00223821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride, extended-release, individually-titrated
Description: Individually-titrated, extended-release oxybutynin chloride with management of side-effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin chloride, extended-release, individually-titrated
Description: Individually-titrated, extended-release oxybutynin chloride with management of side-effects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Training
Description: Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
Study: NCT02629302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: animal assisted therapy
Description: physiotherapy, speech therapy and occupational therapy in the presence of an animal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy
Description: standard physiotherapy, speech therapy and occupational therapy
Study: NCT00676143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
Study: NCT03662568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS4
Description: Administered GLS4 120 mg orally three times daily in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS4
Description: Administered GLS4 120 mg orally three times daily in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS4
Description: Administered GLS4 120 mg orally three times daily in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS4
Description: Administered GLS4 120 mg orally three times daily in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: Administered RTV 100 mg orally three times daily in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: Administered RTV 100 mg orally three times daily in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: Administered RTV 100 mg orally three times daily in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: Administered RTV 100 mg orally three times daily in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV
Description: Administered orally ETV 0.5 mg once daily in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV
Description: Administered orally ETV 0.5 mg once daily in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: Administered TDF 300 mg orally once daily in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: Administered TDF 300 mg orally once daily in fasted state
Study: NCT03318562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eFT508
Description: 200 mg eFT508 dosed BID for 3 week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eFT508
Description: 200 mg eFT508 dosed BID for 3 week cycles
Study: NCT00757653

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip stem with plasma sprayed porous Ti 6Al4V alloy + plasma sprayed HA
Description: Hip stem with plasma sprayed porous Titanium 6Al4V alloy + plasma sprayed HA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA
Description: Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip stem with Interloc Titanium surface + Bonemaster H.A
Description: Hip stem with Interloc Titanium surface + Bonemaster H.A
Study: NCT04399447

Intervention type: RADIATION
Intervention: Echocardiography
Description: left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS

Intervention type: RADIATION
Intervention: Echocardiography
Description: left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS

Intervention type: RADIATION
Intervention: Echocardiography
Description: left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS

Intervention type: RADIATION
Intervention: Echocardiography
Description: left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS

Intervention type: RADIATION
Intervention: Echocardiography
Description: left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS

Intervention type: RADIATION
Intervention: Echocardiography
Description: left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS
Study: NCT02832713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A ( BoNT-A)
Description: Intra-articular injection of BoNT-A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid (HA)
Description: Intra-articular injection of Hyaluronic acid
Study: NCT04133389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Growth mindset of personality educational intervention
Description: This is a brief online educational intervention that teaches growth mindset of personality. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Growth mindset of athletic ability educational intervention
Description: This is a brief online educational intervention that teaches growth mindset of athletic ability. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
Study: NCT00706797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept (EnbrelTM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate